Tatva Chintan Pharma Chem Limited has informed the Exchange about Credit Rating
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.1 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CRISIL Ratings has downgraded Tatva Chintan Pharma Chem's credit ratings on its Rs. 245 crore bank loan facilities. The long-term rating was revised from CRISIL A-/Negative to CRISIL BBB+/Stable, and the short-term rating was lowered from CRISIL A2+ to CRISIL A2. CRISIL cited 'moderation in the business risk profile of the Company' as the reason for the downgrade. The revised outlook on the long-term rating is now Stable, removing the earlier Negative outlook. The downgrade affects facilities across multiple banks including ICICI Bank, SBI, DBS Bank, Citibank, and Axis Bank.
This is a credit negative event that signals weakening business fundamentals and may increase the company's future borrowing costs. Shareholders should expect negative market sentiment, as rating downgrades typically reflect concerns about the company's financial health and growth prospects.